Posters will be presented on 5 November 2015 only.
| P 02 | Monocyte derived dendritic cells (MoDC) generated with CliniMACS prodigy are functional and fulfill requirements for cancer vaccines M. Brüning, T. Ozimkowski, E. Bergschneider, M. Birth, S. Wild, D. Dzionek, Miltenyi Biotec GmbH, Bergisch Gladbach/D |
|---|---|
| P 03 | In vitro evaluation of targeted therapy response in cancer cells by label-free Raman spectral imaging S. El-Mashtoly, H. Yosef, D. Petersen, L. Mavarani, C. Kötting, K. Gerwert, Ruhr University Bochum/D |
| P 04 | Influence of starvation on upregulation of intracellular proangiogenic markers in adipose tissue-derived stem cells S. Thoms, P. Ritter, A. Lavrentiva, T. Scheper, C. Blume, Leibniz Universität Hannover/D |
| P 05 | A flexible scale GMP manufacturing process for clinical grade plasmid DNA vectors K. Bohle, C. Lüer, C. Seitz, A. Ross, H. Ziehr, Fraunhofer ITEM, Braunschweig/D |
| P 06 |
An antibiotic-free strategy for miniplasmid production |
| P 07 |
Fully Automated Cell Separation System for Clinical Scale Separation of CD133+ Cells from Bone Marrow Aspirates |
| P 08 | Towards automated manufacturing of clinical scale gene-modified T cells N. Mockel-Tenbrinck, K. Drechsel, K. Reck, D. Mauer, C. Lehmann, H. Bohnenkamp, V. Huppert, M. Assenmacher, I. Johnston, A. Kaiser, Miltenyi Biotec GmbH, Bergisch Gladbach/D |
| P 09 | Automated Generation of Genetically Modified Human CD34+ Cells in a Functionally Closed System C. Lehmann, Miltenyi Biotec GmbH, Bergisch Gladbach/D; S. Scaramuzza, San Raffaele Telethon Institute for Gene Therapy (TIGET), Milan/I; K. Reck, M. Essl, Miltenyi Biotec GmbH, Bergisch Gladbach/D; R.J. Hernandez, San Raffaele Telethon Institute for Gene Therapy (TIGET), Milan/I; S.L.S Catamancio, C. Bovolenta, MolMed SpA, Milan/I; A. Aiuti, Vita Salute University, Milan/I; I.C.D. Johnston, Miltenyi Biotec GmbH, Bergisch Gladbach/D |
| P 10 |
Pre-clinical biodistribution studies for ATMPs: Insights from a GLP-certified service provider |
| P 11 |
Regulatory Requirements for Medicinal Products Containing Retroviral Vectors
|